No Detail Found!

Comparison of meglumine antimoniate and miltefosine in cutaneous leishmaniasis

Author(s)
Atiya Rahman Department of Dermatology, PNS Shifa Hospital and Bahria University,Karachi,Pakistan
Moizza Tahir Department of Dermatology, Combined Military Hospital,Gujranwala,Pakistan
Tehseen Naveed Department of Dermatology, Combined Military Hospital,Peshawar,Pakistan
Mohammad Abdullah Department of Stroke Medicine, Russells Hall Hospital,Dudley,UK
Nida Qayyum Department of Dermatology, Combined Military Hospital,Multan,Pakistan
Danish Hafeez Malik Department of Dermatology, Combined Military Hospital,Lahore,Pakistan
Bushra Amin Department of Community Medicine, Combined Military Hospital Lahore Medical College,Lahore,Pakistan
Abstract
Objective: To compare the e cacy and safety of meglumine antimoniate and miltefosine in the treatment of cutaneous leishmaniasis in Pakistan. Study Design: Randomised-controlled trial. Place and Duration of the Study: Department of Dermatology, Combined Military Hospital, Lahore and Peshawar, from January to December 2021. Methodology: Smear positive and/or skin biopsy-con rmed cases of cutaneous leishmaniasis in adult males aged between 18-60 years were enrolled after receiving informed consent. Patients were randomly divided into Group A and Group B by lottery method. Group A received intramuscular meglumine antimoniate 15-20mg/kg/day, and Group B received oral miltefosine 50 mg thrice a day for a duration of 28 days. Data were analysed by SPSS 22. E ectiveness and safety of therapeutic agents were calculated by Independent t-test and p-value of 0.05 or less was taken as signi cant. Results: Sixty-six patients, 33 in each group, participated in the study. Total number of cutaneous leishmaniasis lesions were 77 in Group A and 76 in Group B. The duration of lesions was 3.5 months in Group A and 3.2 months in Group B. Treatment response, in terms of complete or near complete resolution of lesions, was signi cantly higher in Group A as compared to Group B (p = 0.011). Both therapeutic agents had considerable side-e ects with more patients withdrawn from Group A as compared to Group B (p = 0.010). Conclusion: Intra-muscular meglumine antimoniate was more e ective in comparison to oral miltefosine in the treatment of cutaneous leishmaniasis. However, e cacy of meglumine antimoniate is mired by its side-e ect pro le. Conclusion: Intra-muscular meglumine antimoniate was more effective in comparison to oral miltefosine in the treatment of cutaneous leishmaniasis. However, efficacy of meglumine antimoniate is mired by its side-effect profile.
Publication Details
Page(s) 1367-1371
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 33, Issue: 12, Year: 2023

Request the full text from PASTIC

Keywords
Safety, Cutaneous leishmaniasis, treatment, meglumine antimoniate, E cacy, Adverse e ects, Miltefosine, Side-e ects, Old world cutaneous leishmaniasis
0

Citations

0

Downloads

65

Views